98%
921
2 minutes
20
Purpose: To investigate the application of imaging biomarkers, including R2*, Fat Fraction (FF) and apparent diffusion coefficient (ADC) values, obtained through Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation for Imaging Quantification (IDEAL-IQ) and DWI techniques, in differentiating P53-mutated and non-mutated HCC.
Patients And Methods: This retrospective study included patients with pathologically confirmed HCC between January 2019 and July 2024. HCC were divided into P53-mutated group and non-mutated group by immunostaining. Preoperative R2*, FF, and ADC values derived from IDEAL-IQ and DWI were compared between the two groups, as well as different histological grades. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performance of each MRI parameter for detecting P53 mutations in HCC, with area under the curve (AUC) compared by Delong's test.
Results: Compared to the non-mutated group, the P53-mutated group (n = 31) showed significantly higher R2* values (34.821 ± 9.980 vs 23.713 ± 5.586, P < 0.001) and lower ADC values (0.760 ± 0.142 vs 0.855 ± 0.130, P = 0.002), while FF values showed no significant difference (P = 0.646). R2*, ADC, and the combined model (R2* + ADC) revealed AUCs of 0.849, 0.726, and 0.856, respectively, with the combined model demonstrating the highest sensitivity and specificity. Additionally, high-grade HCC showed significantly lower ADC values compared to lower-grade tumors (P < 0.001).
Conclusion: R2* and ADC exhibited significant features in P53-mutated HCC, suggesting their potential as non-invasive biomarkers for predicting P53 mutation status and guiding clinical management. The combined use of R2* and ADC may further enhance diagnostic accuracy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336383 | PMC |
http://dx.doi.org/10.2147/JHC.S524533 | DOI Listing |
World J Urol
September 2025
Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Kerpener Str. 62, 50937 , Cologne, Germany.
Objective: To evaluate the expression of trophoblast cell surface antigen-2 (TROP-2), a broadly expressed antibody-drug conjugate (ADC) target, in non-clear cell renal cell carcinoma (nccRCC), and to perform a proof-of-concept analysis assessing the cytotoxic efficacy of the TROP-2-directed ADC Sacituzumab govitecan (SG) in RCC cell lines.
Methods: A cohort comprising clear cell RCC (ccRCC, = 44), papillary (pRCC, = 22), chromophobe (chRCC, = 22), and benign renal tumors ( = 8, including oncocytoma and angiomyolipoma) was analysed using reverse transcription quantitative PCR (RT-qPCR), immunohistochemistry (IHC) with H-score quantification, and enzyme-linked immunosorbent assay (ELISA). In RCC cell lines, TROP-2 protein levels were assessed by Western blotting and flow cytometry, and SG cytotoxicity was evaluated using MTT assays.
J Hepatocell Carcinoma
August 2025
Department of Radiology, Zhongda Hospital, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging and Interventional Radiology, School of Medicine, Southeast University, Nanjing, People's Republic of China.
Purpose: To investigate the application of imaging biomarkers, including R2*, Fat Fraction (FF) and apparent diffusion coefficient (ADC) values, obtained through Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation for Imaging Quantification (IDEAL-IQ) and DWI techniques, in differentiating P53-mutated and non-mutated HCC.
Patients And Methods: This retrospective study included patients with pathologically confirmed HCC between January 2019 and July 2024. HCC were divided into P53-mutated group and non-mutated group by immunostaining.
Nat Commun
August 2025
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
This phase II trial aims to determine the efficacy and safety of frontline acalabrutinib, lenalidomide and rituximab for patients with advanced stage follicular lymphoma (FL) and high tumor burden. The primary endpoint was best complete response (CR) rate; the secondary endpoints were overall response rate (ORR), duration of response measured as CR at 30 months (CR30), progression of disease at 24 months (POD24) rate, progression-free survival (PFS), overall survival and safety. Twenty-four patients with previously untreated FL were included in this phase 2 single arm study (NCT04404088).
View Article and Find Full Text PDFClin Cancer Res
July 2025
MD Anderson Cancer Center, Houston, TX, United States.
Introduction: SIRPα+ macrophages can mediate resistance to lenalidomide and rituximab (R2) in patients with B-cell non-Hodgkin lymphoma (B-NHL). Evorpacept (ALX148) is a novel CD47 blocker that abrogates interactions between lymphoma cells and SIRPα+ macrophages.
Methods: Adult patients with B-NHL who had received at least 2 prior lines of systemic therapy were included in this single arm phase I study (NCT05025800).
NMR Biomed
September 2025
Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Multimodality imaging is an emerging research topic in neuro-oncology for its potential of being able to demonstrate tumours in a more comprehensive manner. Diffusion-weighted magnetic resonance imaging (dMRI) and proton magnetic resonance spectroscopy (H-MRS) allow inferring tissue cellularity and biochemical properties, respectively. Combining dMRI and H-MRS may provide more accurate diagnosis for paediatric brain tumours than only one modality.
View Article and Find Full Text PDF